Spruce Biosciences Inc

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company is engaged in the development of TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with MPS IIIB (Sanfilippo Syndrome Type B). It also provides the development stage of Tildacerfont, aimed at treating a highly debilitating mental disorder characterized by depressed mood, cognitive-affective changes, somatic alterations including anhedonia, weight fluctuations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia. Spruce Biosciences has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. Furthermore, it has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.